INFLUENCE OF LONG TERM ERYTHROPOIETIN THERAPY ON THE HYPOTHALAMIC–PITUITARY–THYROID AXIS IN PATIENTS UNDERGOING CAPD

Figures & data

Table 1. Baseline and Stimulated Hormonal Concentrations in Uremic Patients on CAPD Therapy and Healthy Controls

	Patients
	Before rHuEpo	After rHuEpo	Controls
fT3, pg/mL	2.62±0.13	2.74±0.26	3.09±0.21
fT4, ng/mL	1.07±0.061^a	1.12±0.061^a	1.41±0.10
TSH basal, uIU/L	2.47±0.441^a	2.11±0.43	1.30±0.17
TSH peak, uIU/L	7.53±1.65	5.27±1.032*	8.56±1.38
TSH AUC, uIU h/L	1027.98±204.35	785.80±148.452*	938.31±150.09
GH basal, mIU/L	18.18±11.341^b	10.88±6.471^c	1.34±1.26
GH peak, mIU/L	29.18±8.961^c	22.01±6.081^c	1.49±0.68
GH AUC, mIU h/L	2547.66±912.351^c	1907.41±643.791^c	115.45±48.99
	27.66±4.111^a	23.70±3.851^a	12.40±3.23
Prolactin peak, ng/mL	41.45±7.37	42.53±7.90	28.37±3.88
Prolactin AUC, ng h/mL	6316.14±1133.851^a	6185.51±1094.591^a	2885.65±388.65

vs. healthy controls (Mann-Whitney U-test): ^ap < 0.05; ^bp = 0.001; ^cp < 0.001.

vs. before treatment (Wilcoxon Signed rank test): *p < 0.05.

Figure 1. TSH responses to TRH administration in patients on CAPD before and after correction of anemia with rHuEpo and healthy controls.

Figure 2. Prolactin responses to TRH administration in patients on CAPD before and after correction of anemia with rHuEpo and healthy controls.

Figure 3. GH responses to TRH administration in patients on CAPD before and after correction of anemia with rHuEpo and healthy controls.